AYGEN, Bilgehan et al. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology, [S. l.], v. 31, n. 4, p. 305–317, 2020. DOI: 10.5152/tjg.2020.19197. Disponível em: https://www.turkjgastroenterol.org/index.php/tjg/article/view/3574. Acesso em: 1 jan. 2026.